(Q38066657)

28 August 2017

1 reference

title

The Fra-2 transgenic mouse model of systemic sclerosis (English)

1 reference

28 August 2017

Britta Maurer

1

1 reference

28 August 2017

Jörg H W Distler

series ordinal

2

1 reference

28 August 2017

Oliver Distler

series ordinal

3

1 reference

28 August 2017

publication date

8 December 2012

1 reference

28 August 2017

published in

Vascular Pharmacology

1 reference

28 August 2017

volume

58

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

194-201

1 reference

Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Animal models of systemic sclerosis: prospects and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

7 January 2021

The heart in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

AP-1: a double-edged sword in tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Transcription factor AP-1, and the role of Fra-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Inflammation, growth factors, and pulmonary vascular remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Pathologic assessment of vasculopathies in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Updated clinical classification of pulmonary hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Changes in causes of death in systemic sclerosis, 1972-2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Digital ulcers: overt vascular disease in systemic sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2012.12.001

10.1016/J.VPH.2012.12.001

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference